[Skip to Content]
[Skip to Content Landing]
Views 397
Citations 0
Comment & Response
April 25, 2017

Evolocumab Added to Statins to Reduce Progression of Coronary Atherosclerosis

Author Affiliations
  • 1Department of Cardiovascular Medicine, Royal Liverpool University Hospital, Liverpool, United Kingdom
JAMA. 2017;317(16):1690. doi:10.1001/jama.2017.3440

To the Editor Dr Nicholls and colleagues found that adding evolocumab vs placebo to statin treatment among patients with coronary disease resulted in a 1% greater decrease in percent atheroma volume (PAV), measured by serial intravascular ultrasonography (IVUS) imaging, after 76 weeks.1 Unfortunately, IVUS examinations have inherent variability.2 Even in the best of laboratories, there are always measurement reproducibility errors but also intraoperator and interoperator variability in the actual plaque measurements.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×